Przeglad menopauzalny = Menopause review · 2026
Estrogen receptor status low status in breast cancer: clinicopathological factors and prognostic value.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huszno Joanna, Kołosza Zofia, Stobiecka Ewa, Ponikiewska Dorota, Szcześniak Bogna, Simek Jakub, Chmielik Ewa
Аннотация
INTRODUCTION: We aimed to investigate the prognostic significance of estrogen receptor status (ER)-low status in breast cancer (BC). Additionally, we compared the ER-low subgroup with ER-negative and ER-high BC according to clinical, histopathological and molecular factors.
MATERIAL AND METHODS: The analysis included medical records of BC patients treated at the National Institute of Oncology in Gliwice, Poland, between 2002 and 2018.
RESULTS: Of the 657 tumours, 14% were classified as ER-low, 52% as ER-high and 34% as ER-negative. Patients with ER-low tumours were more likely to present with T3-T4 disease compared with those with ER-high (19% vs. 12%, p = 0.089) and less frequently than ER-negative (19% vs. 29%, p = 0.092). Patients with ER-low tumours were less likely to be progesterone receptor status (PgR) negative (19% vs. 92%, p < 0.001) and G3 (22% vs. 49%, p < 0.001) compared with ER-negative. BRCA P/LP (pathogenic/likely pathogenic) variants were less frequent in ER-low than in ER-negative tumours (5% vs. 20%, p = 0.001). Overall survival (OS) was similar in both ER-high and ER-low groups (p = 0.333; 5-year OS: 93% vs. 92%, 7-year OS: 86% vs. 83%). Overall survival was non-significantly better for those with ER-low compared with ER-negative (p = 0.107).
CONCLUSIONS: Estrogen receptor-low status appears to be associated with a higher T stage and PgR negativity compared with ER-high tumours, and with a lower grade and fewer BRCA P/LP variants compared with ER-negative tumours. A trend toward improved OS was observed in ER-low compared with ER-negative patients.
MATERIAL AND METHODS: The analysis included medical records of BC patients treated at the National Institute of Oncology in Gliwice, Poland, between 2002 and 2018.
RESULTS: Of the 657 tumours, 14% were classified as ER-low, 52% as ER-high and 34% as ER-negative. Patients with ER-low tumours were more likely to present with T3-T4 disease compared with those with ER-high (19% vs. 12%, p = 0.089) and less frequently than ER-negative (19% vs. 29%, p = 0.092). Patients with ER-low tumours were less likely to be progesterone receptor status (PgR) negative (19% vs. 92%, p < 0.001) and G3 (22% vs. 49%, p < 0.001) compared with ER-negative. BRCA P/LP (pathogenic/likely pathogenic) variants were less frequent in ER-low than in ER-negative tumours (5% vs. 20%, p = 0.001). Overall survival (OS) was similar in both ER-high and ER-low groups (p = 0.333; 5-year OS: 93% vs. 92%, 7-year OS: 86% vs. 83%). Overall survival was non-significantly better for those with ER-low compared with ER-negative (p = 0.107).
CONCLUSIONS: Estrogen receptor-low status appears to be associated with a higher T stage and PgR negativity compared with ER-high tumours, and with a lower grade and fewer BRCA P/LP variants compared with ER-negative tumours. A trend toward improved OS was observed in ER-low compared with ER-negative patients.